Introduction
In hematological malignancy, recurrent chromosomal translocations are frequently observed, which cause aberrant gene expression or generate abnormal chimeric genes (Look, 1997) . To date, many targeted genes involved in chromosomal translocations have been identi®ed. However, the normal function of each gene as well as the role of the chimeric gene product in oncogenicity still remains to be elucidated.
AML1 (RUNX-1/PEBP2aB/CBFa) (Miyoshi et al., 1991; Ogawa et al., 1993) is one essential regulatory gene in de®nitive hematopoiesis (Okuda et al., 1996; Wang et al., 1996) , and the most frequently disrupted gene in acute myelogenous leukemia (AML) (Look, 1997) . Recent reports suggest that point mutations in AML1, which will introduce loss of function, are also observed in a particular subset of AML (Osato et al., 1999; Song et al., 1999) . Moreover, PEBP2b/CBFb, whose product is the heterodimeric partner of AML1, is rearranged in AML with inv(16) (Liu et al., 1993) . These reports suggest that dysfunction of PEBP2/CBF is critical to certain types of leukemia.
AML1 takes various fusion partners as a chimeric oncogene, and each chromosomal translocation is well associated with clinical features and cytological abnormalities (Friedman, 1999; Ito, 1999) : AML1-MTG8 (ETO) in t(8;21) almost always observed in AML with dierentiation (Downing, 1999; Erickson et al., 1992; Kozu et al., 1993; Miyoshi et al., 1993) ; AML1-MTG16 in t(16;21) associated with secondary leukemia or myelodysplastic syndrome (MDS) (Gamou et al., 1998) ; AML1-EVI-1 in t(3;21) with blast crisis of chronic myelogenous leukemia (CML) (Mitani et al., 1994) ; TEL-AML1 in t(12;21) in acute lymphoid leukemia (ALL) (Romana et al., 1995) . Such a correlation of karyotype abnormalities with cytological and clinical features is not explained only by dysfunction of AML1, therefore, it is necessary to consider at which stage hematopoietic stem/progenitor cells require the normal function of MTG8, MTG16, EVI1, or TEL, and at which level malignant transformation occurs.
MTG8 is a member of a phylogenically highly conserved protein family; MTG8(ETO/CDR) (Erickson et al., 1992; Kozu et al., 1993; Miyoshi et al., 1993; Nisson et al., 1992) , MTGR1(EHT) (Fracchiolla et al., 1998; Kitabayashi et al., 1998) , and MTG16(MTGR2) (Calabi and Cilli, 1998; Gamou et al., 1998) in human, and Drosophila nervy (Feinstein et al., 1995) . MTG8 has unique motifs: three prolineserine-threonine (PST) rich regions and four conserved regions among MTG8/nervy family named NHR (nervy homology region) (Kitabayashi et al., 1998) , NHR1 (also called TAF110 homology region), NHR2 (or hydrophobic heptad repeat, HHR), NHR3 and NHR4 (or zinc ®nger domain, ZnF/MYND domain (MTG8-nervy-DEAF1)) (Gross and McGinnis, 1996) . NHR2 is the domain through which MTG8 family proteins form a homo-or heterodimer complex (Davis et al., 1999; Kitabayashi et al., 1998) . ZnF makes contact with nuclear co-repressors such as N-coR and SMRT, resulting in recruitment of histone deacetylase (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998) . The role of NHR1 and NHR3 has not been clari®ed.
MTG8 has been found in neuronal cells (Sacchi et al., 1998) and hematopoietic cells (Erickson et al., 1996) , although the mRNA of MTG8 seems to be highly expressed in heart and brain, and at low level in other tissues (Wolford and Prochazka, 1998) . Whether MTG8 exists in the nucleus or cytoplasm, varies from cell to cell, whereas AML1 and AML1-MTG8 are recognized as nuclear proteins (Erickson et al., 1996) .
We have reported that MTG8 is able to transform BALB/3T3 ®broblast cells in cooperation with H-ras (Sueoka et al., 1998) . Another group showed that introduction of MTG8 alone into NIH3T3 cells can cause tumorigenicity (Wang et al., 1997) . On the other hand, the colony formation activity of AML1-MTG8 in ®broblasts requires NHR2 domain of MTG8 as well as the runt domain of AML1 (Frank et al., 1999) . Although these studies utilized non-hematopoietic cells, their ®ndings re¯ect the signi®cance of the tumorigenic activity of MTG8. t(16;21)(q24;q22) bears AML1-MTG16 whose construct is similar to AML1-MTG8 (Gamou et al., 1998) . To repress dierentiation in L-G murine myeloid leukemic cells by using exogenous AML1-MTG8, MTGR1 seems to be required, forming a complex with AML1-MTG8 (Kitabayashi et al., 1998) . Deletion of MTGR1/EHT is found in about 10% of clinical AML samples (Fracchiolla et al., 1998) . These results suggest that not only AML1 but also MTG8, MTGR1 and MTG16 play an important role in leukemogenesis.
In order to de®ne the physiological function of MTG8 and to address the leukemogenicity of AML1-MTG8, we searched for MTG8 binding proteins using the yeast two-hybrid system. Here we report that MTG8 interacts, through the NHR3 domain, with the N-terminus of the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RIIa). Type I PKA is predominantly cytosolic, whereas type II PKA is mainly localized to distinct subcellular structures directed by interaction with PKA (or A-kinase) anchoring proteins (AKAPs) (Colledge and Scott, 1999; Faux and Scott, 1996) . Type II PKA is thought to phosphorylate target proteins at subcellular compartments determined by binding with AKAP. We propose that MTG8 is an AKAP, especially at the centrosome-Golgi area in lymphocytes.
Results

Identification of a novel interaction between MTG8 and RIIa
In order to ®nd proteins interacting with MTG8, yeast two-hybrid screening was performed using the fulllength MTG8 as bait. From a human adult brain cDNA library, seven clones were obtained as His + bgal + candidates. One of the clones, Br5, encoded the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RIIa). Br5 contained sequences from the 5'-untranslated region (UTR) to N-terminal coding region of RIIa (aa 1 ± 80). In order to avoid non-speci®c binding of peptides derived from 5'-UTR of RIIa, we generated GAL4 AD-fused RIIa encoding the N-terminal 80 amino acids. Rematching by b-gal assay in yeast showed that MTG8 speci®cally interacted with RIIa (data not shown).
MTG8 interacts with RIIa in vitro and in leukemic cells
To con®rm the interaction between MTG8 and RIIa in vitro, pull-down assay was performed ( Figure 1a ). Recombinant proteins of full-length MTG8 tagged with S-peptide (S-MTG8) and GST-RIIa (aa 1 ± 80) were expressed in E. coli. S-MTG8 was shown to bind immobilized GST-RIIa, but not to GST ( Figure 1a , upper panel). Natural MTG8 in HEL cell extracts also bound to GST-RIIa ( Figure 1a , middle panel). Immobilized S-MTG8 was able to retain RIIa in HEL cell extracts ( Figure 1a , lower panel), although the interaction was weak.
Next, we examined if MTG8 and RIIa interact in the cells. To this end, a mammalian two-hybrid assay using K562 leukemic cells was employed. The N-terminus of RIIa (aa 1 ± 80) was fused to GAL4 DBD, and fulllength MTG8 to VP16AD. MTG8 speci®cally interacted with RIIa ( Figure 1b ). Therefore, MTG8 is able to interact with RIIa in vitro and in vivo.
Binding sites of MTG8 and RIIa
In order to identify the binding sites of MTG8 and RIIa, deletion mutants of GAL4 DBD-MTG8 and GAL4 AD-RIIa were generated and b-gal assay was performed in the yeast two-hybrid system. To determine the binding site in MTG8, the full-length (aa 1 ± 577) and various deletion mutants of MTG8 (aa 1 ± 553, 1 ± 479, 1 ± 409, 1 ± 307, 1 ± 193, 1 ± 93, 94 ± 193, 194 ± 307, 308 ± 409, 410 ± 479, 480 ± 553 , 554 ± 577, 1 ± 577 except 423 ± 460) fused with GAL4 DBD were coexpressed with GAL4 AD-fused RIIa (aa 1 ± 80) in yeast Y190, and b-gal assay was performed ( Figure 2a ). To determine the binding site in RIIa, full-length (aa 1 ± 404) or deletion mutant of RIIa (aa 81 ± 404, 1 ± 80, 1 ± 45 and 5 ± 45) fused with GAL4 AD was coexpressed with GAL4 DBD-fused MTG8 (aa 1 ± 577) in Y190 (Figure 2b ). For binding to RIIa, aa 410 ± 479 of MTG8, including NHR3 domain conserved among MTG8 family proteins, were necessary ( Figure 2a ). The binding to MTG8 occurred at aa 5 ± 45 of RIIa, through which RIIa associates with PKA anchoring proteins (AKAPs) (Figure 2b ) (Newlon et al., 1999) .
In general, the binding domain in AKAP for RII is thought to form a unique structure: an amphipathic ahelix which has a hydrophobic face and a hydrophilic face (Colledge and Scott, 1999; Newlon et al., 1999) . The hydrophobic side of the helix is thought to interact with the N-terminal region of regulatory subunits of PKA. In view of this point, NHR3 contains a putative a-amphipathic helix (Figure 3a) . Moreover, on alignment of the amino acids through which AKAP is MTG8 interacts with RIIa in PBL T Fukuyama et al thought to interact with the regulatory subunit of type II PKA, MTG8 seems to have conserved amino acids among other AKAPs such as AKAP79, Ht31, or MAP-2 (Carr et al., 1991) in the amphipathic region ( Figure 3b ). Therefore, MTG8 is a candidate for a novel AKAP based on its binding site in RIIa and structural similarity to other AKAPs in MTG8.
Endogenous MTG8 and RIIa interact in normal PBL at the centrosome-Golgi area
We wondered whether endogenous MTG8 and RIIa interacted in PBL. In PBL, MTG8 mRNA expression was detected by RT ± PCR at low level, compared to in HEL leukemic cells expressing MTG8 at high level and HL-60 as a negative control (Figure 4a ). Western blotting analysis also showed that a low level of MTG8 was expressed in PBL ( Figure 4b ). Immunoprecipitation with anti-RIIa antibody coprecipitated endogenous MTG8, indicating signi®cant interaction of MTG8 and RIIa in PBL (Figure 4c , upper). However, MTG8 and RIIa did not co-immunoprecipitate in HEL cells (Figure 4c, lower) . Next, we analysed whether or not MTG8 and RIIa are overlapped in PBL by indirect immuno¯uorescence confocal microscopy ( Figure 5 ). FITC-signals (green) were predominantly seen in the cytoplasm as dense spots. TRITC-signals (red) showed a similar pattern of distribution. Because RIIa is known to exist predominantly at the centrosome-Golgi area Nigg et al., 1985; Skalhegg et al., 1994) , MTG8
and RIIa were overlapped in PBL mainly in this area. This implies that MTG8 would be an AKAP at the centrosome-Golgi area in PBL.
Discussion
The proto-oncogene MTG8 was originally found as part of the leukemic fusion gene, AML1-MTG8 (Erickson et al., 1992; Kozu et al., 1993; Nisson et al., 1992) . MTG8 is expressed ubiquitously in human tissue, although its expression levels are quite dierent from tissue to tissue: higher in brain, heart, and muscle; lower in hematopoietic tissues (Wolford and Prochazka, 1998) . MTG8 protein exists in the nucleus in malignant cells, such as HEL cells that express MTG8 at high level, and in cells transduced with it exogenously (Erickson et al., 1996; Le et al., 1998) . Recently, MTG8 was identi®ed as a transcriptional suppressor by its tight association with the nuclear matrix (Le et al., 1998; McNeil et al., 1999) and recruitment of N-coR and HDACs (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998) . However, the cytoplasmic localization of MTG8 in some brain tissues (Sacchi et al., 1998) and in PBL (in this report) is reported.
PKA is one of the best-studied and most essential protein kinases, being involved in various physiological functions. PKA holo-enzyme consists of two regulatory subunits and two catalytic subunits (Tasken et al., 1997) . Four regulatory subunits (RIa, RIb, RIIa, RIIb) ) cells were transfected with pG5E1bLuc (1 mg), pRL-TK (2 ng), and eector plasmids (1 mg each) for expression of GAL4 DBD-(pM or pM-RIIa) or VP16 AD-(pVP16 or pVP16-MTG8) fused protein. Relative luciferase activity was assessed by dividing the value of Fire¯y luciferase expression activity by that of Renilla luciferase expression activity and three catalytic subunits (Ca, Cb, Cg) exist as independent gene products. PKA is categorized as type I or II. Type II PKA is localized at subcellular structures by binding through RII with AKAP (Colledge and Faux and Scott, 1996) . AKAP binds to the intracellular compartment, such as plasma membrane, cytoskeleton, mitochondria, or nuclear membrane, and tethers type II PKA so that it can phosphorylate speci®c target proteins directed by AKAP. RII is known to dimerize with the N-terminal 45 aa, and interact with AKAP (Newlon et al., 1999) . The structure of AKAP bound to RII is a characteristic amphipathic a-helix. Indeed, we found in this study that RIIa interacts with MTG8 through the AKAP-binding domain of RIIa (Figure 2a,b) , whereas NHR3 of MTG8, which is revealed as the binding site to RIIa, is predicted as amphipathic a-helix ( Figure  3a ). In addition, NHR3 has similarity in binding sites with other AKAPs (Figure 3b) . Moreover, indirect immuno¯uorescence microscopy showed that MTG8 and RIIa were co-localized mainly at the centrosomeGolgi area in PBL ( Figure 5 ). Therefore, MTG8 may function as an AKAP, especially at the centrosomeGolgi area in PBL. This suggests that MTG8 would play an important role in cell cycle control, protein secretion, or cytokinesis. Although we showed that MTG8 was expressed in PBL by RT ± PCR and Western blotting, we could not rule out that MTG8 family proteins, MTGR1 and MTG16, also make contact with RIIa. Further study is required to elucidate whether MTG8 family proteins act as AKAPs. Several AKAPs at the centrosome-Golgi area have been reported to date, including AKAP450 (Witczak et al., 1999) , CG-NAP (Takahashi et al., 1999) and AKAP350 (Schmidt et al., 1999) , in several cell lines. However, judging from the alignment of their cDNA sequences, they seem to be identical or alternative splicing variant products. Hence, MTG8 is another group of AKAPs at the centrosome-Golgi area. AKAP is reported to function as a multivalent anchoring protein for kinase and phosphatase. For example, AKAP79 harbors protein kinase C (PKC) and phosphatase 2B (calcineurin, CaN) along with type II PKA (Klauck et al., 1996) . CG-NAP is also reported to associate with Protein kinase N (PKN) and catalytic subunits of protein phosphatase 2A and 1 in addition to type II PKA (Takahashi et al., 1999) . These AKAPs are thought to organize various signaling cascades at speci®c subcellular structures. The possibility that MTG8 is a multivalent signal modulator is now under examination. Although CG-NAP is shown to localize at the centrosomes in the mitotic phase, the staining by anti-MTG8 in S phase is diuse in HEL cells (data not shown). It would be interesting to study the relationship among MTG8 and CG-NAP/AKAP450/Yotiao throughout the cell cycle. Also, target substrates as well as their functional changes, for example microtubules Figure 5 Indirect immuno¯uorescence staining of MTG8 and RIIa in PBL. Freshly isolated PBL were prepared on slides using cytospin, and stained simultaneously with anti-MTG8 (rabbit IgG) and anti-RIIa (mouse IgG) antibodies as ®rst antibody. FITCconjugated anti-rabbit IgG and TRITC-conjugated anti-mouse IgG were used as secondary antibody. The stained cells were analysed by confocal microscopy and their organization, modulated by these kinases and phosphatases organized by MTG8 and AKAP450/CG-NAP should be explored.
Materials and methods
Yeast two-hybrid screening and assay
The full-coding sequence of the cDNA of MTG8a was inserted into pAS2-1 to generate a fusion protein with the GAL4 DNA binding domain (DBD) (MATCHMAKER Two-hybrid system, Clontech). Yeast two-hybrid screening was performed using Y190 yeast cells among 3610 6 clones of a normal human brain cDNA library (Clontech) with pAS2-1-MTG8 as bait plasmid. His + b-gal + candidate clones were puri®ed, and sequence analysis was performed using ABI PRISM 310 or 377 (PE Applied Biosystems). In order to obtain the series of MTG8 and RIIa deletion constructs, PCR-ampli®ed cDNA of mutant MTG8 or RIIa was inserted into pAS2-1 or pACT2, for a fusion protein with the GAL4 activation domain (AD). To study the interaction of MTG8 and RIIa, plasmids for expressing GAL4 DBD-MTG8 and GAL4 AD-RIIa were introduced into Y190. b-galactosidase (b-gal) assay was performed according to the manufacturer's recommendation (Clontech).
Cell lines, purification of peripheral blood lymphocytes (PBL) and culture HEL, HL-60 and K562 leukemic cell lines were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS). Peripheral blood lymphocytes (PBL) were obtained from normal peripheral blood using Ficoll-Paque (Amersham Pharmacia Biotech).
Pull-down assay
To obtain cell extracts, HEL cells (5610 6 ) were suspended in 200 ml of cold lysis buer A (0.5% Triton X-100, 10 mM EDTA, pH 7.5, protease inhibitor mixture (complete, Boehringer Mannheim) in PBS). After incubation on ice for 20 min, the cell suspension was sonicated, and centrifuged at 15 000 r.p.m. for 15 min at 48C. The supernatant was used as cell extract. Recombinant S-tagged full-length MTG8 produced in E. coli was previously described (Komori et al., 1999) . To generate recombinant GST-RIIa (aa 1 ± 80) protein in E. coli, cDNA of RIIa was inserted into pGEX4T.1 (Amersham Pharmacia Biotech). For immobilization of S-MTG8 or GST and GST-RIIa, S-beads (Invitrogen) or glutathione Sepharose 4B beads (GS4B, Amersham Pharmacia Biotech) were used. Immobilized GST and GSTRIIa or S-beads and S-MTG8 were incubated with soluble S-MTG8 or HEL cell extracts for 3 h at 48C with gentle rotation. Bound proteins were washed in lysis buer A three times, and separated by 10% SDS ± PAGE. For immunoblotting, SDS ± PAGE gel was transferred to PVDF membrane (Sequi-Blot PVDF Membrane, BIO-RAD). Blocking of the membrane was performed in TBS-T (Tris-buered saline, pH 7.6, with 0.1% of Tween 20 (Sigma)) with 0.5% Casein for 3 h or overnight, then washed in TBS-T. Polyclonal anti-MTG8 antibodies were raised in rabbit with GST-MTG8 (aa 87 ± 189) or with MTG8 peptide (aa 286 ± 303). Anti-MTG8 or monoclonal anti-RIIa (Transduction Laboratories) antibodies were used as primary antibody, and anti-rabbit IgG or anti-mouse IgG conjugated with horseradish peroxidase (Amersham Pharmacia Biotech) was used as secondary antibody. The ECL system (Amersham Pharmacia Biotech) was used for the detection of proteins.
Mammalian two-hybrid assay cDNA of RIIa (aa 1 ± 80) was inserted into pM (Clontech) for GAL4 DBD-fused protein (pM-RIIa) and that of MTG8 into pVP16 (Clontech) for VP16AD-fused protein (pVP16-MTG8). Reporter gene plasmid (pG5E1bLuc), carrying Fire¯y luciferase gene, was produced by inserting the GAL4 UAS G 65-E1b TATA region of pG5CAT (Clontech) into pGL3-basic vector (Promega). One microgram of pM or pMRIIa, and pVP16, pVP16-MTG8 were transfected with 1 mg of pG5E1bLuc and 2 ng of pRL-TK (Promega) for control Renilla luciferase expression. K562 (1610 6 ) cells were transfected using 5 ml DMRIE-C (GIBCO ± BRL) in 6-well plates. Twenty-four hours after transfection, cells were lysed and assayed using the Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was evaluated by dividing the value of Fire¯y luciferase activity by that of Renilla luciferase activity.
Reverse-transcription polymerase chain reaction (RT ± PCR) analysis
Total RNA from 1610 7 cells of PBL, HEL, or HL-60 was extracted with ISOGEN (Nippongene). The RT reaction was performed with 50 ng of RNA using RNA LA PCR Core Kit (Takara). PCR was performed with Ampli-Taq Gold. Primers for MTG8 were 5'-TTT GAC AGA GAG CCT TTG CA-3' for sense and 5'-TTC TGT CCC TGA GGT CCC TGT GGC TGG-3' for antisense. Primers for b-actin were 5'-GTG GGG CGC CCC AGG CAC CA-3' for sense and 5'-CTC CTT AAT GTC ACG CAC GAT TTC-3' for antisense. The conditions were pre-incubation at 948C for 2 min, denature at 948C, annealing at 598C and extension at 728C for 30 s with 32 cycles. PCR products were run on 1.5% agarose gel with ethidium bromide. PCR products of MTG8 were con®rmed by direct sequence analysis.
Immunoprecipitation assay
Cell extracts of PBL and HEL were prepared as described above. In order to deplete non-speci®c binding proteins, 50 ml of Pansorbin (Calbiochem) pre-washed in lysis buer A was added to cell extracts. After incubation with gentle rotation for 30 min at 48C, the cell suspension was centrifuged at 15 000 r.p.m. for 1 min at 48C, and the supernatant was collected and used. Normal mouse serum (NMS) or polyclonal anti-RIIa antibody (Santa Cruz) was added to cell extract and incubated for 3 h at 48C with gentle rotation. Twenty micrograms of 50% slurry Protein-G Sepharose (Amersham Pharmacia Biotech) was added to the cell extract and incubated with gentle rotation for 1 h at 48C. The bound proteins were washed three times in lysis buer A, and separated by 8% SDS ± PAGE.
Indirect immunofluorescence microscopy
PBL cells were spread on slides coated with 3-aminopropyl triethoxy silane (Matsunami) by cytospin. After one wash with PBS brie¯y, cells were ®xed in PBS with 0.2% Triton X-100 and 4% paraformaldehyde for 10 min, washed in PBS three times for 5 min, and immersed in PBS with 1.0% bovine serum albumin (BSA) for 10 min. Anti-MTG8 (rabbit IgG) and anti-RIIa (mouse IgG, Transduction Laboratories)
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T Fukuyama et al antibodies were incubated for 45 min at room temperature. After three washes in PBS, cells were incubated with antirabbit IgG conjugated with FITC and anti-mouse IgG with TRITC (Sigma). After three more washes in PBS, cells were mounted in mounting media (DAKO) and analysed by confocal microscopy (Zeiss).
